Junshi Biosciences

EqualOcean and Skepsos Sign Strategic Cooperation Memorandum of Understanding

On May 20, 2025, Beijing EO Technology Co.,Ltd and the Greater Paris Health Industry Park (Skepsos) officially signed a Memorandum of Understanding on Strategic Cooperation in Beijing.

Trump Launches "Section 232 Investigations" into Semiconductors and Pharmaceuticals

China's First Modified New Drug of Docetaxel Successfully Went to the US

Under the Fractured Global Supply Chain, How Is United Imaging Shaping a Global "Chain"

Under the Fractured Global Supply Chain, How Is United Imaging Shaping a Global "Chain" Connection?

How Can MedTech Leverage Technological Innovation and Strategic Precision to Go-Global

How Can MedTech Companies Leverage Technological Innovation and Strategic Precision to Expand Globally? | Highlights from GGF2024

HealthGuard: Registration of Indonesian Subsidiary, Investment in Producing HPV Vaccine

SINOVAC Plans to Invest USD 100 Mn in Brazil Starting This Year

EqualOcean has learned that on June 4, Vice President of the Federative Republic of Brazil and Minister of Development, Industry, Trade, and Services, Geraldo Alckmin, met with SINOVAC(科兴) Chairman, President, and CEO Yin Weidong(尹卫东) in Beijing.

Yilite Technology Completes A+ Round Financing of CNY 100 Million

Yilite Technology has secured over CNY 100 million in two rounds of financing within the year.

Cellatopia Secures Nearly CNY Ten Mn in Seed Funding

EqualOcean has learned that Cellatopia(喜同生物), a biotechnology company based in Suzhou, recently announced the successful securing of nearly CNY ten million in seed funding. The funding was primarily led by Suzhou Shishangbai Venture Capital(苏州石上柏创业合伙企业) and followed by institutions such as Suzhou Nuowei Venture Investment Limited(苏州诺为创业投资有限公司).

Haier Biomedical 'Smart Blood City Network' Lands in Brazil

Brazil, as the largest country and economy in South America, faces numerous challenges brought about by an aging population. With the country's economy continuing to grow, healthcare issues are receiving increasing attention, and the demand for medical services is rising year by year.

D3 Bio Completes A+ Round Financing, Accelerates Development of Product Pipeline

EqualOcean has learned that on April 8, 2024, D3 Bio(德昇济医药), a biotechnology company focused on the development and commercialization of innovative cancer and immune precision therapies, announced the successful completion of its A+ round financing led by Medicxi, a prominent European life sciences investment firm. The financing amounted to USD 62 million, with existing investor, Matrix Partners(经纬创投), also participating.

Yanyin Technology raised tens of millions of yuan in angel round financing

Recently, Yanyin Technology announced that it has completed tens of millions of yuan in angel round financing, and the investor is Qiming Venture Partners.

EqualOcean | Southern Weekly 2022 'China Greenwashing List'

Nine companies have been listed on China's Greenwashing List, drawing wider attention to the issue of greenwashing.

EqualOcean｜China's Top 20 ESG Performers Among Private Enterprises（Part III）

Private enterprises are actively embracing the transformative era

Ligatech Completes D Round of Financing of hundreds of Millions

Recently, Shanghai Ligatech Bioscience Co., Ltd(利格泰), located in Qingpu District, Shanghai, announced the completion of a D round of financing of hundreds of Millions.

Lanja has completed the Series A funding of hundred millions CNY

Shanghai Lanja Medical Technology Co., Ltd (“Lanja”) recently has announced the completion of the Series A funding of hundred millions CNY.

Cataya Completes B Round of Financing of 250 Million

The synthetic biology company Shanghai Cataya Biotech Inc. (柯泰亚生物) has recently announced the completion of a RMB 250 million B round of financing.

RabPharma has completed the Series A+ funding of hundred millions CNY

Zhongshan RabPharma Biopharmaceutical Co., Ltd. (“RabPharma”) recently has announced the completion of the Series A+ funding of hundred millions CNY.

Powertight has completed a pre-Series A funding of hundred millions CNY

Powertight Biotechnology (Hangzhou) Co., Ltd. (“Powertight”) recently has announced the completion of a pre-Series A funding of hundred millions CNY.

Foremed Legend has completed the pre-Series A+ funding

Suzhou Foremed Legend Medical Technology Company, Ltd. (“Foremed Legend”) recently has announced the completion of pre-Series A+ funding.